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Radiotherapy plays an important role in the treatment for thoracic cancers. Accurate diagnosis is essential to correctly perform
curative radiotherapy. Tumor delineation is also important to prevent geographic misses in radiotherapy planning. Currently,
planning is based on computed tomography (CT) imaging when radiation oncologists manually contour the tumor, and this
practice often induces interobserver variability. F-18 ﬂuorodeoxyglucose positron emission tomography (FDG-PET) has been
reported to enable accurate staging and detect tumor extension in several thoracic cancers, such as lung cancer and esophageal
cancer. FDG-PET imaging has many potential advantages in radiotherapy planning for these cancers, because it can add biological
information to conventional anatomical images and decrease the inter-observer variability. FDG-PET improves radiotherapy
volume and enables dose escalation without causing severe side eﬀects, especially in lung cancer patients. The main advantage
of FDG-PET for esophageal cancer patients is the detection of unrecognized lymph node or distal metastases. However, automatic
delineation by FDG-PET is still controversial in these tumors, despite the initial expectations. We will review the role of FDG-PET
in radiotherapy for thoracic cancers, including lung cancer and esophageal cancer.
1.Introduction
Radiotherapy plays an important role in the treatment
of thoracic cancers, such as non-small-cell lung cancer
(NSCLC), small-cell lung cancer (SCLC), and esophageal ca-
ncer [1, 2]. Recent advances in accurate diagnosis improve
the practice of curative radiotherapy, because patients with
unsuspected metastases may avoid unnecessary local ther-
apies and receive necessary systemic treatment. Accurate
delineation of tumor volume is also important to prevent
geographic misses in treatment planning. Indeed, an under-
estimation of tumor extension will result in tumor recur-
rence. In contrast, overestimation of the extension may in-
crease unnecessary side eﬀects. Therefore, delineation of tu-
mor volumes is a crucial factor in curative radiotherapy.
Currently, treatment planning is based on computed
tomography (CT) imaging to contour the tumor. Tumor de-
lineation is manually performed by each radiation oncolog-
istinclinicalpractice,whichleadstointerobservervariability
in tumor delineation. Accurate delineation of tumor volume
requires the identiﬁcation of anatomic borders of tumors
based on accurate diagnosis. F-18 ﬂuorodeoxyglucose posi-
tron emission tomography (FDG-PET) and PET/CT have
been reported to enable accurate staging and to detect the
tumor extension compared with CT alone [3]. FDG-PET
imaginghasmanypotentialadvantagesinradiotherapyplan-
ning, because it can add biological information combined
with anatomical information by CT imaging. Radiotherapy
planning based on FDG-PET is expected to decrease the
interobserver variability amongst thoracic radiation oncol-
ogists. In addition to accurate staging, FDG-PET has the po-
tential to improve radiotherapy planning by its precise
delineation of primary tumor and lymph nodes. Indeed,
FDG-PET has been investigated as tracer for radiotherapy
planning in many cancer types [4] .I nt h i sp a p e r ,w ef o c u so n
the role of FDG-PET in radiotherapy for thoracic cancers,
including NSCLC, SCLC, esophageal cancer, and breast ca-
ncer.2 International Journal of Molecular Imaging
2.Non-Small-CellLungCancer(NSCLC)
2.1. Staging. Thoracic radiotherapy is a key modality of the
management for NSCLC patients. Accurate staging is crucial
forlungcancerpatientsbecausetreatmentstrategyandprog-
nosisdrasticallydiﬀeraccordingtoclinicalstage.CTimaging
contributes to the initial determination for the staging of
NSCLC and provides morphologic information of the dis-
ease extension. Currently, FDG-PET is performed to diag-
nose the stage and evaluate the eﬀects of the treatment in
clinical use for NSCLC patients. One of the important roles
of FDG-PET is to detect unsuspected lymph nodes or ex-
trathoracic metastases [5, 6]. A prospective study has re-
ported that FDG-PET detected unsuspected metastasis in
20% of candidates for radical radiotherapy, changing their
treatment strategies [7]. Furthermore, the same authors
showedthatearlymortalityratewaslowinpatientsstagedby
FDG-PET compared with those staged by conventional ima-
ging, on the basis of their accurate staging [8]. Another
prospective study demonstrated that curative radiotherapy
in 27% of patients was not qualiﬁed by FDG-PET because
of distant metastasis or extensive locoregional disease [9]. In
this study, 32% of patients were upstaged after PET staging.
Bradley et al. also reported that FDG-PET altered radiation
planning in over 50% of patients staged by CT imaging,
due to the detection of unsuspected nodal disease, metastatic
disease, or tumor extension from atelectasis [10]. As seen in
these ﬁndings, the incorporation of FDG-PET improves the
accuracy of staging and patient selection, providing better
treatment strategy including radiotherapy planning.
2.2. FDG-PET for Tumor Volume Delineation. FDG-PET is
increasingly performed to deﬁne tumor volume for radio-
therapy in patients with NSCLC. Accurate contouring of
organs is important for radiotherapy and PET imaging is
currently expected to be useful in the delineation of gross
tumor volume (GTV) [11]. In this section, we reviewed the
published literature on delineation of GTV in NSCLC pa-
tients.
Several methods have been examined for GTV delin-
eation after the introduction of FDG-PET (Table 1)[ 12–25].
Visual interpretation is a simple method to incorporate PET
information with CT imaging. However, this method arbi-
trarily depends on the window levels set of the PET images.
Therefore, the display of PET data should be standardized.
Several articles have reported the use of standardized up-
takevolume(SUV) inGTVidentiﬁcation. PaulinoandJohn-
stone have suggested using SUV of 2.5 to autocontour GTV
[12]. Hong et al. compared target volume delineation by
FDG-PET with that by CT imaging in 19 patients with
NSCLC, concluding that SUV of 2.5 should be used for
radiotherapy planning in NSCLC patients [18]. Another me-
thod was the use of the ratio of SUV. Erdi et al. analyzed a
phantom with lung lesion by source-to-background ratios
[13].Theyappliedthisdatato10patientswith17primaryor
metastatic lung lesions, concluding that the source-to-back-
ground ratio was useful in the deﬁnition of tumor volumes.
Nestle et al. compared GTVs obtained from four diﬀer-
ent methods: visually (GTVvis), applying a 40%-threshold
of SUV max (GTV40), using an autocontour of SUV 2.5
(GTV2.5), and using an algorithm by phantom measure-
ments (GTVbg) in 25 patients with NSCLC [14]. In the re-
sults, GTVvis, GTV2.5, and GTVbg were relevant to the CT-
derived GTV, whereas GTV40 appeared unsuitable for target
volume delineation.
Recently, some studies reported a new gradient-based
method relied on the water shed transform and hierarchical
cluster analysis. This method provided denoised and de-
blurred images with an edge-preserving ﬁlter and a con-
strained iterative deconvolution algorithm, leading a better
estimation of the gradient intensity. Wanet et al. compared
a gradient-based segmentation method, a source-to-back-
ground ratio method, and a 40% to 50% of SUV max me-
thod with surgical specimens of 10 patients with NSCLC
[15]. All patients underwent image inspections before sur-
gery. Among several methods, the gradient-based method
achieved the best results, with the lowest average error and
smallest standard deviation. Werner-Wasik et al. conducted
the same experiment using the digital thorax phantom and
evaluated the accuracy and consistency of three methods:
gradient-based PET segmentation, manual, and constant
threshold methods [16]. They concluded that the gradient-
basedmethodwasthemostaccuratewiththeleastsystematic
bias at any phantom size.
Despite these several techniques for the delineation of
tumor volume having been reported in recent years, a gold
standard method has not been established to contour GTV
automatically. However, FDG-PET has the additional infor-
mation that aids radiation oncologists to delineate GTV, in-
dicating that FDG-PET should be utilized when tumor vol-
ume is delineated in NSCLC patients.
2.3.ReductionofInterobserverVariability. Interobservervari-
abilityinregardtoGTVdeﬁnitionisaseriousprobleminthe
treatment planning for NSCLC [26, 27]. Caldwell et al. pro-
spectively evaluated the role of FDG-PET in interobserver
variability in 30 NSCLC patients [28]. Three radiation on-
cologists contoured GTV using CT alone or FDG-PET
registered CT (PET/CT). The mean coeﬃcient of variation
for GTV based on PET/CT was signiﬁcantly smaller than CT
alone (P<0.01). Recently, van Barrdwijk et al. also reported
that PET/CT-based autocontouring decreased interobserver
variability in delineation of the primary tumor and nodal
legions [29]. These studies indicated that FDG-PET can re-
duce interobserver variability in radiotherapy treatment
planning.
2.4. Role of FDG-PET in Stereotactic Radiotherapy for Early-
Stage NSCLC. Currently, more patients have been treated
by stereotactic body radiotherapy (SBRT) for early-stage
NSCLC [1, 2]. Recent studies reported the role of FDG-PET
in SBRT for NSLCL, such as staging, treatment response, and
planning. Henderson et al. performed serial planned FDG-
PET (before and after SBRT) in stage I NSCLC patients treat-
ed by 60–66Gy in three fractions [30]. In their study, sub-
stantial proportion of patients had moderately elevated
SUVmax at 52 weeks after SBRT without evidence ofInternational Journal of Molecular Imaging 3
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local failure, suggesting that slight elevation of SUVmax
should not be surrogate for local failure. Andratschke et al.
performed SBRT that consisted of 3–5 fractions with 7–
15Gy per fraction in 92 stage I NSCLC patients [31].
Most patients were staged according to FDG-PET. Isolated
regional recurrence was observed in only 7.6%. The authors
concluded that elective irradiation can safely be omitted in
stage I NSCLC after accurate nodal staging with PET-CT.
Takeda et al. evaluated the correlation between pretreat-
ment SUVmax on FDG-PET and local recurrence in 95
patients with NSCLC [32]. Total dose of SBRT was 40–50Gy
in ﬁve fractions. Two-year local recurrence rates for lower
SUVmax (<6.0) and higher SUVmax (≥6.0) were 93% and
42%, respectively (P<0.001). Multivariate analysis showed
that only the SUVmax of a primary tumor was a signiﬁcant
predictor for local recurrence (P = 0.002). The authors
concluded that a high SUVmax might be considered for dose
escalation to improve local control in NSCLC. Hoopes et al.
alsoreportedthat58patientswithmedicallyinoperablestage
I NSCLC treated by SBRT [33]. Total doses ranged from
24 to 72Gy in three fractions. In their study, pretreatment
SUVmax did not predict three-year overall survival or local
control. Coon et al. performed SBRT with a dose of 60Gy in
three fractions for stage I NSCLC (n = 26), recurrent lung
cancer (n = 12), and solitary lung metastases (n = 13) [34].
Most patients received PET-CT before and after SBRT. PET-
CT was valuable in staging, treatment planning, but no cor-
relations were found between pretreatment SUVmax and
treatment response, disease progression-free survival, and
overall survival.
These ﬁndings suggest that FDG-PET is useful for ac-
curate staging and treatment planning in stage I NSCLC
treated by SBRT. However, it has been controversial whether
pretreatment SUVmax is prognostic factor for treatment
outcomes,suchaslocalcontr olandov erallsurvival.P r ospec-
tivestudiesarewarrantedtoestablishtheroleofFDG-PETin
SBRT for NSCLC patients.
2.5. Role of FDG-PET on Evaluation for Tumor Recurrence.
ForpatientswithNSCLC,localfailureafterradiationtherapy
is a signiﬁcant issue. Sura et al. reported FDG-PET as a me-
thod to assume the pattern of local failure after radiation
therapy [35]. They analyzed the data of 26 patients with 34
recurrent legions that were contoured using a ﬁxed threshold
of 42% of the maximum SUV by post-RT PET/CT. The
result showed that the pattern of recurrence depended on the
radiation dose. At a total dose of <60Gy, most recurrences
were within target volume. At a total dose of 60Gy, re-
currences were within the marginal zone of the target vol-
ume.
Similarly, Abramyuk et al. also reported the detection of
recurrenceusingPET/CT[36].TheyevaluatedwhetherPET/
CT is capable of predicting the location of recurrence in
patients with NSCLC, especially for determining high-risk
area in tumor. Ten patients with local failure of NSCLC were
analyzed. After radiation therapy, 2 patients’ lesions had a
complete metabolic response and 8 patients’ lesions showed
reduced SUV. However, all patients were diagnosed with
recurrence 12 months after the radiation therapy. The loca-
tion of recurrence was mostly in the most active metabolic
lesion(threshold>35%ofSUVmax)ofprimarytumor.This
result may be applied to further radiation therapy of addi-
tional doses to the area of higher FDG uptake.
2.6. Role of FDG-PET in Elective Nodal Irradiation. Elective
nodal irradiation to the mediastinal lymph regions in the
treatment of stage III NSCLC patients is still a controversy
[37, 38]. Rosenzweig et al. retrospectively evaluated the fail-
ure rates in uninvolved nodal regions with involved-ﬁeld
radiotherapy for inoperable 524 patients with NSCLC. The
2-year elective nodal control rate was 91% and the authors
concluded that involved-ﬁeld radiotherapy did not cause a
signiﬁcant amount of failure in lymph node regions [39].
RTOG0117 also performed involved-ﬁeld radiotherapy to
perform high-dose irradiation without severe side eﬀects
[40]. However, some clinicians have raised the concern that
omission of elective nodal irradiation requires a further dis-
cussion, because recurrence of lymph nodes is usually fatal
and microscopic metastasis of lymph nodes occurs substan-
tially in advanced NSCLC [38].
FDG-PET can contribute to accurate evaluation of nodal
lesions,comparedwithCTalone[41,42].DeRuysscheretal.
conducted a prospective study of involved-ﬁeld radiotherapy
b a s e do nF D G - P E Tf o r4 4p a t i e n t s[ 43]. In this study, only 1
patient (2.3%) developed an isolated nodal failure, and the
authors concluded that FDG-PET was useful in the in-
volved-ﬁeld radiotherapy for NSCLC patients. Furthermore,
Kolodziejczyk et al. reported that FDG-PET should be used
even in the elective nodal irradiation planning for NSCLC,
because elective nodal irradiation may not compensate the
unsuspected mediastinal lymph nodes [9]. It is controversial
whether elective nodal irradiation can be safely omitted by
FDG-PET or not. However, this strategy is extremely attrac-
tive because it allows radiation-dose escalation without se-
vere side eﬀects. Further studies are warranted to establish
the utility of FDG-PET in NSCLC for radiation planning.
3.Small-CellLungCancer(SCLC)
3.1. Staging. SCLC accounts for 20–25% of all newly diag-
nosed lung cancers. SCLC often represents an aggressive
clinical course and high incidence of distant metastasis be-
cause of rapid tumor growth. Despite aggressive treatment,
the prognosis remains poor [44].
Although accurate staging is essential for determining
the treatment strategy in SCLC, it is diﬃcult to evaluate the
extension of disease accurately, and especially mediastinum
lymphnodemetastases.Fischeretal.prospectivelyexamined
the role of PET/CT compared with standard staging (CT and
bone scintigraphy) in 29 SCLC patients [45]. In their study,
PET/CTchangedthestagein5ofthe29patients(17%),with
the authors concluding that PET/CT improves the accuracy
ofstaginginSCLC.Inotherstudies,8.3%to9.5%oflimited-
disease SCLC staged by the conventional staging proce-
dures was upstaged to extended-disease SCLC after FDG-
PET information was incorporated [46, 47]. Arslan et al.International Journal of Molecular Imaging 5
evaluated the accuracy and overall survival staged by FDG-
PET or CT imaging [48]. PET scan upstaged 9 (36%) in
25 patients and downstaged 2 (8%) in 25 patients who were
staged by CT imaging. Furthermore, FDG-PET staging pre-
dicted signiﬁcant survival diﬀerence (P = 0.019), while CT
imaging did not (P = 0.055). These studies recommended
that FDG-PET should be performed for initial staging in
limited-disease SCLC patients.
3.2. FDG-PET for Tumor Volume Delineation. Compared
with NSCLC, few studies have been performed regarding the
delineationbasedonFDG-PETforSCLC.FDG-PETinSCLC
patients may improve the delineation of tumor volume as
well as NSCLC.
3.3. Involved Field-Based FDG-PET Planning. For limited-
disease SCLC, elective nodal irradiation for mediastinal ly-
mph node regions has been considered necessary to reduce
lymph node failure. However, some clinicians have attemp-
ted to avoid elective nodal irradiation because extended
radiotherapy volume leads to severe side eﬀects. Baas et al.
conducted a phase II study of involved-ﬁeld radiotherapy
for limited-disease SLCL staged by CT imaging [49]. They
reported median survival of 19.5 months and low incidence
of adverse eﬀects. De Ruysscher et al. also conducted a phase
II trial of involved-ﬁeld irradiation based on CT imaging for
limited-disease SCLC [50]. They evaluated overall survival
and isolated nodal failure deﬁned as recurrence in regional
nodes outside the target volume in the absence of in-ﬁeld
failure.Intheirstudy,isolatedmediastinallymphnoderecur-
rence was unexpectedly high (11%). Given these ﬁndings, a
report from the International Atomic Energy Agency (IAEA)
consultants’meetingindicatedthatinvolved-ﬁeldirradiation
in SCLC was controversial and should be performed in a
prospective clinical trial [51].
Currently, FDG-PET is expected to determine whether
elective nodal irradiation is necessary or not. Two recent
studies have shown the usefulness of FDG-PET in omitting
elective nodal irradiation in SCLC [52, 53]. van Loon et al.
conducted a prospective study of involved-ﬁeld irradiation
on the basis of FDG-PET for 60 patients with limited-disease
SCLC [52]. Median actuarial overall survival was 19 months
and isolated nodal failures was low (3%). The authors
concludedthattreatmentplanningbasedonFDG-PETcould
decrease isolated nodal failures, compared with their pre-
vious results (isolated nodal failure: 11%) treated by CT-
based involved-ﬁeld irradiation. Shirvani et al. reported that
involved-ﬁeld irradiation by intensity-modulated radiother-
apy (IMRT) for 60 patients with limited-disease SLCL was
staged by FDG-PET [53]. In this study, the 2-year actuarial
overall survival was 58% and isolated elective node was ob-
served in only one patient (3%). These studies concluded
that elective nodal irradiation could be safely omitted by
FDG-PET staging in SCLC. Avoidance of mediastinal lymph
nodes that are PET-negative can lead to (1) a reduction of
toxicity with the same radiation dose or (2) dose escalation
with the same toxicity. Although involved-ﬁeld irradiation
based on FDG-PET is an attractive treatment in SCLC, there
is not enough information to recommend the strategy. Fur-
ther prospective studies are required to determine whether
elective nodal irradiation can be safely omitted by FDG-PET
staging in SCLC.
Another possible role of FDG-PET in SCLC is in the
evaluation of the therapeutic response. A preliminary study
showed that FDG-PET could predict the outcome of treat-
ment by radiotherapy or chemotherapy [54].
In conclusion, the role of FDG-PET in SCLC has been es-
tablished for staging use. Although the use of FDG-PET in
radiation treatment planning for SCLC is still controversial,
involved-ﬁeld irradiation based on FDG-PET is an attractive
strategy.FDG-PET-basedtreatmentplanningwillchangethe
strategy for limited-disease SCLC.
4. Esophageal Cancer
In the treatment of esophageal cancer, radiotherapy is com-
monly used in combination with chemotherapy. Currently,
radiotherapy requires accurate target volume deﬁnition
based on treatment planning by CT scan. Although plan-
ning-CT-based target volume deﬁnition is considered the
gold standard in esophageal cancer, applying FDG-PET to
treatment planning may have several advantages, such as ac-
curate staging and delineation of tumor.
4.1. Staging. FDG-PET has been considered useful in the
staging process of esophageal cancer [55]. Flamen et al. re-
ported that 70 primary tumors of 74 patients were detected
by FDG-PET, with a sensitivity of 95% [56]. However, 4 pa-
tients with T1 lesions were not detected by FDG-PET. The
authors showed that FDG-PET had a higher accuracy for
stage IV disease compared with conventional modalities
(82% versus 64%, P = 0.004). Van Vliet et al. performed a
meta-analysis to evaluate the diagnostic performance of CT
and FDG-PET in staging of esophageal cancer [57]. The
sensitivities of CT and FDG-PET for regional lymph node
metastases were 0.50 and 0.57, respectively, and their speci-
ﬁcities were 0.83 and 0.85, respectively. The detection of
distant metastases by FDG-PET was signiﬁcantly higher than
CT. The authors concluded that each modality plays a dis-
tinctive role in the detection of esophageal cancer.
4.2. FDG-PET for Tumor Volume Delineation. Accurate de-
lineation of esophageal tumor is important for successful ra-
diotherapy. The additional information provided by FDG-
PET is expected to improve tumor delineation and accurate
staging of lymph nodes and distant metastases. Several stud-
ies have investigated the optimal method for delineating the
target volume by FDG-PET. Most studies used visualized in-
terpretation for tumor delineation [58–61]. Moureau-Za-
botto et al. evaluated the eﬀect of the addition of FDG-PET
to CT in tumor delineation of 34 esophageal cancer patients
[59]. FDG-PET decreased the length of GTV in 12 patients
(35%) and increased the length in 12 patients (35%).
Konski et al. used SUV 2.5 to delineate the tumor exten-
sion and evaluated the CT-based tumor length in 25 eso-
phageal cancer patients [62]. The authors concluded that6 International Journal of Molecular Imaging
FDG-PETprovidesadditionalinformationfortheidentiﬁca-
tion of GTV. Zhong et al. compared FDG-PET-based tumor
length with surgical specimens and showed that SUV 2.5
seemed closest to the pathological length [63]. Hong et al.
reported that automated interpretation of FDG-PET using
mean activity of the liver plus 2 standard deviations likely
aﬀect target deﬁnition [64]. Recently Vali et al. compared
11 diﬀerent methods: SUV 2.0, 2.5, 3.0, and 3.5; SUV Max
40%, 45%, and 50%; mean liver SUV plus 1, 2, 3, and 4
standard deviations [65]. The authors concluded that the use
of a threshold of approximately 2.5 was the optimal method
for the delineation of GTV in esophageal cancer, regardless
of SUV thresholding method.
Recent studies indicated that SUV 2.5 may be an optimal
threshold, but autocontouring using this threshold is not
satisfactory. Further investigations are required to utilize
FDG-PET in the tumor delineation for esophageal cancer in
clinical use.
4.3. Interobserver Variability. Another method to utilize
FDG-PET in treatment planning is to reduce interobserver
variability. Schreurs et al. evaluated the tumor volumes de-
lineated by FDG-PET in 28 esophageal cancer patients by
three radiation oncologists [66]. The authors concluded that
FDG-PET might improve target volume deﬁnition with less
geographicmisses,buttheeﬀectsoninterobservervariability
were not signiﬁcant. Vesprini et al. compared FDG-PET/CT
with CT alone for the identiﬁcation of GTV in 10 patients
with esophageal cancer by 6 radiation oncologists [60]. The
addition of FDG-PET signiﬁcantly decreased both inter- and
intraobserver variability.
4.4. The Eﬀect of FDG-PET on Radiotherapy Planning. Muijs
et al. reported that the additional use of FDG-PET led to
the modiﬁcation of CT-based radiotherapy planning in
57% of esophageal cancer patients [61]. Furthermore, they
showed that FDG-PET signiﬁcantly changed the radiation
dosefororgansatrisk,suchasheartandlung.Theadditional
information provided by FDG-PET has the possibility of
improving the local control due to less geographic misses.
However, there are no studies that showed whether FDG-
PET aﬀects survival or local control rate. Further studies are
warranted to establish the role of FDG-PET in highly ac-
curate radiotherapy planning for esophageal cancer.
5. Prospects of PET Imagingfor
Thoracic Cancers
5.1. Respiratory-Gated PET Imaging. One of the limitations
intheuseofPETimaginginradiotherapyplanningisthelow
spatial resolution. Generally, the spatial resolution of current
PET scanners (6–8mm) is inferior to that of modern CT
scanners (1mm) [67]. Furthermore, because PET requires
several minutes to perform the imaging, tumor motion due
to respiration or cardiac action deteriorates PET images and
increases diagnostic errors in thoracic cancers. In fact, it is
one of the major limitations of FDG-PET in several tumor
typesandhasbeenlargelyresponsiblefortheslowacceptance
of FDG-PET when major treatment decisions are made on
the basis of a negative FDG-PET. Respiratory-gated PET
imaging is currently expected to improve the quantiﬁcation
of PET [68]. Sakaguchi et al. reported that gated imaging
acquisition improved the quality of FDG-PET imaging in
a moving phantom model [69]. Daouk et al. evaluated 48
pulmonary nodules in 43 patients by respiratory-gated PET
and ungated method [70]. Gated imaging had higher sen-
sitivity and speciﬁcity than the ungated method, especially
for smaller lesions located in lower lobes. These ﬁndings
suggested that respiratory-gated PET should be performed
for patients with thoracic cancers with respiratory motions.
5.2. FLT-PET. Other nuclides have been investigated to
overcome the problems of FDG-PET. Currently, 3 -deoxy-
3 -(18)F-ﬂuorothymidine (FLT), a PET imaging marker of
proliferation, has been introduced as an alternative to FDG
f o rl u n gc a n c e r[ 71]. Yang et al. compared the diagnostic
eﬃcacy of FLT-PET and FDG-PET in NSCLC [72]. The
sensitivities of FLT- and FDG-PET for primary tumor
were 74% and 94%, respectively. In contrast, FLT-PET
showed better speciﬁcity and accuracy than FDG-PET for
lymph nodes. Although the use of FLT-PET is still at an
investigational level, further studies are expected to continue
to evaluate its eﬃcacy.
When PET is used for radiotherapy planning, a range
of uncertainties related to technical, physical, biological, and
analytical factors must be considered. Further investigations
arewarrantedtoestablishhighlyaccurateradiotherapybased
on PET imaging for thoracic cancers.
6. Summary
FDG-PET plays a pivotal role in accurate staging and selec-
tion of patients to be treated by radiotherapy. Furthermore,
FDG-PET improves radiotherapy volume and enables dose
escalation without severe side eﬀects in lung cancer patients.
The main advantage of FDG-PET for esophageal cancer pa-
tients is the detection of unrecognized lymph nodes or distal
metastases. While FDG-PET was initially expected to result
in more accurate target delineation, its eﬃcacy remains con-
troversial and delineation by FDG-PET should not be prac-
ticed in clinical use at this stage. Further studies are required
to conﬁrm the advantage of FDG-PET in radiotherapy plan-
ning for thoracic cancers.
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